11.01.12
In an effort to continue the development of its nutraceutical and drug pipeline, Biophytis, a research company that focuses on metabolic disorders and age-related diseases, has raised €2 million ($2.6 million) in a B round. Metabrain Research, a spin-off of Merck Serono based in Chilly-Mazarin, France, joined existing investors Seventure partners and CM-CIC Capital Prive in this round.
Biophytis’ first project, SARCOB, targets the treatment of sarcopenic obesity, in partnership with the Myology Institute and Institute of Cardio-metabolism and Nutrition, both at the University of Pierre and Marie Curie (UPMC), and France’s national agricultural research institute, INRA. The second project, MACULIA, focuses on treating age-related macular degeneration, in collaboration with UPMC’s Institut de la Vision and Iris Pharma, a contract research organization dedicated to ophthalmology. Biophytis leads these two projects, which are sponsored by the Medicen competitivity cluster in the Paris region that benefit from grants of €2.3 million EUR from a number of European and French local and national government bodies.
Biophytis’ first project, SARCOB, targets the treatment of sarcopenic obesity, in partnership with the Myology Institute and Institute of Cardio-metabolism and Nutrition, both at the University of Pierre and Marie Curie (UPMC), and France’s national agricultural research institute, INRA. The second project, MACULIA, focuses on treating age-related macular degeneration, in collaboration with UPMC’s Institut de la Vision and Iris Pharma, a contract research organization dedicated to ophthalmology. Biophytis leads these two projects, which are sponsored by the Medicen competitivity cluster in the Paris region that benefit from grants of €2.3 million EUR from a number of European and French local and national government bodies.